Inhibrx is a biologic immunotherapeutic company focused on the treatment of high unmet medical needs in oncology, infectious disease and inflammatory conditions.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/inhibrx” connections=”true” suffix=””]
Inhibrxs proprietary platforms enable fit-for-function biotherapeutics that optimally interface with the biology of each target antigen, focus immune activation and mediate enhanced signaling.
In Aug 2012, Inhibrx out licence its first NBRX-103 antibody to Celgene Corp. in deal with potential value of $500 Mn, including up-front, clinical and regulatory milestone payments and royalties on commercial sales.
In July 2015, Inhibrx grants Five Prime Therapeutics exclusive, worldwide rights to develop and commercialize Inhibrxs preclinical glucocorticoid-induced tumor necrosis factor receptors (GITRs) antibody program. Under the terms, Five Prime paid $10 Mn up front and as much as $442.5 Mn in either cash or Five Prime stock, in undisclosed clinical, regulatory and sales milestones.